Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
18 sept. 2023 08h00 HE
|
Medigene AG
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the Baader Investment Conference 2023
11 sept. 2023 12h30 HE
|
Medigene AG
Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 11h00 HE
|
Medigene AG
Planegg/Martinsried, September 5, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes
30 août 2023 17h00 HE
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof....
Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update
17 août 2023 02h00 HE
|
Medigene AG
Pipeline expansion into neoantigens with multiple KRAS mutations as the first targets Acquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch protein Data from MDG1015 and multiple...
Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
16 août 2023 14h30 HE
|
Medigene AG
Planegg/Martinsried, August 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies
22 juin 2023 12h10 HE
|
Medigene AG
Planegg/Martinsried, 22 June 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene to Present Data Highlighting the Enhanced Tumor Cell Killing Effects of Adding the PD1-41BB Switch Receptor to Multiple TCR-T Therapies at the Immuno-Oncology Summit Europe
14 juin 2023 09h00 HE
|
Medigene AG
Planegg/Martinsried, June 14, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors
13 juin 2023 08h00 HE
|
Medigene AG
Planegg/Martinsried, June 13, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs
01 juin 2023 07h00 HE
|
Medigene AG
Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from...